

FPR – 2020 / 0776

Boehringer Ingelheim Vetmedica / Russia 200569928

**CERTIFICATE of ANALYSIS**

**Product name:** VETMEDIN S 1.25 mg chewable tablets  
**Batch number:** 418D0AA  
**Importing country:** Russia  
**Quantity:** 7748 x 50 tablets in ALU/ALU blister foils and carton box  
**Date of manufacture:** 04/2020  
**Expiry date:** 04/2023  
**No. of Analytical card:** QC-0418A-01-033-02/2020  
**Testing specification:** LAV-SPV-033 v04


Parameters, method	Specification	Result
1. Appearance (visual)	brownish, oval, divisible, centre scored tablets	complies
2. Friability (Ph.Eur 2.9.7)	≤ 1.0% (taken from IPC)	0.2
3. Resistance to crushing (Ph.Eur. 2.9.8)	≤ 90 N	39
4. Loss on drying (Ph.Eur 2.2.32)	≤ 5.0%	3.4
5. Uniformity of dosage units (Ph.Eur. in force 2.9.40 Mass uniformity)	Acceptance value ≤ 15.0	2.6
6. Dissolution (Ph.Eur. 2.9.3 Paddle method 75 rpm/min, 45 min.)	Q: 75%	
• S1 (6 units)	No single value < 80% Mean ≥ 75%	83-95 mean: 88
• S2 (12 units)	No single value < 60% Mean ≥ 75%	N/A N/A
• S3 (24 units)	No single value < 50% 22 out of 24 values ≥ 60% Mean ≥ 75%	N/A N/A N/A
7. Microbiological quality* (Ph.Eur. 5.1.4, 2.6.12 and 2.6.13 Plate count method)		
7.1. TAMC (Total aerobic microbial count)	≤ 10 <sup>3</sup> CFU/g	---
7.2. TYMC (Total combined yeasts/moulds count)	≤ 10 <sup>2</sup> CFU/g	
7.3. Escherichia coli	absent in 1 g	
8. Related substances (UHPLC/UV)		
8.1. Impurity A	≤ 0.5 %	< LOQ <sup>2</sup>
8.2. Impurity B	≤ 0.5 %	< LOQ <sup>2</sup>
8.3. Any other impurity	≤ 0.5 %	< LOQ <sup>2</sup>
8.4. Total impurities	≤ 1.0 %	< LOQ <sup>2</sup>
9. Identification of active ingredient (UHPLC/UV)	Rt and the UV-VIS spectrum of the main peak is similar to RS	complies
10. Assay (UHPLC/UV) Pimobendan	1.19 – 1.31 mg/tablet (95 - 105 % of label claim)	1.23 98

\*Not routinely, every 10<sup>th</sup> batch and at least once per year

1: Test is carried out on a spot-check basis. We confirm however compliance with the inspection and requirements also for this batch.  
 2: LOQ: 0.006% for all impurities

**Qualification:** *accepted*

Kistarcsa, 25/05/2020

.....  
  
 Dóra Benesóczki  
 QA QC Manager

**LAVET Kft./Ltd.**  
 Meghatalmazott személy/  
 Qualified person (1.)

.....  
  
 dr. Brigitta Szabó  
 Qualified person




LAVET GYÓGYSZERIPARI KFT. / LAVET PHARMACEUTICALS LTD.  
 Minőségbiztosítási Osztály / Quality Assurance/ Meghatalmazott személy / Qualified Person  
 Gyógyszergyártási engedély száma / Manufacturing authorisation No.: MA-HU/18V/2006/M14  
 GMP igazolás száma/GMP certificate No.: CG-HU/14V/2019, CG-HU/18V/2019, CG-HU/04V/2019  
 Cím/Address: H-2143 Kistarcsa, Batthyány utca 6., Hungary - Tel: (+36) 28/506-445  
 E-mail: [lavet@lavet.hu](mailto:lavet@lavet.hu)  
[www.lavet.hu](http://www.lavet.hu)

**CERTIFICATE OF CONFORMITY**

Product's name, strength	VETMEDIN S 1.25 mg chewable tablets
Active ingredient(s)	Pimobendan
Manufacturing specification:	GYÁR-047 v10
Batch number	418D0AA
Importing country:	Russia
Quantity	7748 x 50 tablets in ALU/ALU blister foils and carton box
Manufacturing date:	04/2020
Expiry date:	04/2023
Testing specification:	LAV-SPV-033 v 04

Statement:

I hereby certify that the above information is authentic and accurate. This batch of product has been manufactured, including packaging and quality control at the above mentioned site(s) in full compliance with the GMP requirements of the local Regulatory Authority and with the specifications in the Marketing Authorisation of the importing country. The batch processing, packaging and analysis records were reviewed and found to be in compliance with GMP. Any deviations have been assessed prior to batch release. The batch has been released by a Qualified Person.

Name and position of person authorizing batch release for shipment	dr. Brigitta Szabó Qualified Person
Signature	

**LAVET Kft./Ltd.**  
 Meghatalmazott személy/  
 Qualified person (1.)

Date of signature: 25/05/2020